🔗 Share this article

While the US continues making unprecedented adjustments to its immunization recommendations, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by questioning Covid shots throughout the pandemic and has concentrated on alleged deaths following Covid immunization in her brief position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Agency leaders planned to reveal radical revisions to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a significant shift that would place the US out of step with much of the global community with no evidence for improved outcomes. The announcement has been postponed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to present at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

A New Direction at the FDA

The acting appointment may indicate a closer partnership between the drug and biologics branches as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon reevaluating already-approved vaccines at the FDA.

The new acting director has repeatedly called for halting certain pediatric vaccine recommendations in the US so as to align more in line with Denmark's approach, a nation with nationalized medicine and a citizenry approximately the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccination policy – typically the responsibility of Dr. Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Expertise

The appointee has no obvious track record in pharmaceutical research, regulation or administrative roles, which has been standard for previous directors of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the CDER, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in managing a sizeable institution. She has no expertise in industry regulation.”

Former commissioners of the center would “be deeply familiar with regulatory frameworks and the science of medication creation”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that former directors who ran the center have had.”

This division has an enormous range of responsibilities at the FDA, she stated.

“The public just focuses on the novel medication approvals, but the generic program clears numerous generic drugs. There’s a biosimilars division, OTC medication office and more, and every single one need to be managed,” she said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a significant leadership component to the position, which oversees in excess of 5,000 employees. “It is a enormous leadership role, if you perform it correctly,” Woodcock said.

Agency Reaction and Contentious Programs

When asked about inquiries about Høeg’s credentials and whether this selection signifies more teamwork among regulatory chiefs on immunizations, a representative stated that the “concerns stem from incorrect assumptions”.

“Her experience aligns with the functions of her role,” the spokesperson stated, noting the months Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a contentious one-day drug-approval program that allegedly troubled her predecessors. “By what process are these medications being chosen for this fast-track system? Who makes the decisions?” Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he remarked, “the agency looks to be trending towards laxer rules of pharmaceuticals, except for vaccines.”

Documented Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if troubling, track record, some experts have noted. She published a analysis using non-validated public submissions to determine the frequency of heart inflammation after COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “desired changes” for the current government featured revising rules for new vaccines and discontinuing “unnecessary” vaccines, she remarked following the vote on a audio program. At the agency, Høeg has according to sources floated the idea of excluding adolescent males from getting COVID-19 vaccinations.

“She is an thorough true believer who begins with her preconceived notions and tailors the evidence to fit the evidence in a highly deceptive, fraudulent manner,” Howard said.

Taking Control and a “Revenge Tour”

Høeg aligned with fellow dissenters, {like|